Personalis (NASDAQ:PSNL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Personalis (NASDAQ:PSNL) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $11.00 price objective on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $7.25 price target on shares of Personalis in a research report on Friday, December 20th.

Personalis Stock Performance

NASDAQ PSNL opened at $5.60 on Wednesday. The stock’s fifty day moving average is $4.69 and its two-hundred day moving average is $4.32. The firm has a market capitalization of $395.63 million, a P/E ratio of -3.33 and a beta of 1.75. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $25.71 million for the quarter, compared to analyst estimates of $20.67 million. During the same period in the previous year, the firm posted ($0.51) EPS. As a group, sell-side analysts forecast that Personalis will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PSNL. Jane Street Group LLC boosted its position in shares of Personalis by 154.3% during the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after purchasing an additional 99,671 shares during the period. ARK Investment Management LLC raised its position in Personalis by 11.4% in the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after purchasing an additional 723,637 shares during the period. Walleye Capital LLC acquired a new position in Personalis during the third quarter worth $897,000. Barclays PLC boosted its position in shares of Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the period. Finally, State Street Corp grew its stake in shares of Personalis by 34.5% in the third quarter. State Street Corp now owns 175,142 shares of the company’s stock valued at $942,000 after buying an additional 44,900 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.